Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy consists of the gonadotropin-releasing hormone (GnRH) agonist triptorelin and the steroid hormone progesterone, utilized as luteal phase support (LPS) in assisted reproductive technology (ART) cycles, such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). Triptorelin acts as an agonist at the GnRH receptor in the pituitary gland, inducing a surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) that stimulates the corpora lutea to enhance endogenous steroid synthesis. Progesterone provides direct exogenous hormonal support to the endometrium, facilitating embryo implantation and maintaining early pregnancy. This specific investigational protocol typically involves a single mid-luteal dose of triptorelin (0.1 mg) administered subcutaneously on day 6 after oocyte pickup, in addition to standard transvaginal progesterone supplementation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triptorelin + progesterone.